Pharmetheus: Advancing model informed drug development

Demands from payors and regulators for differentiated products necessitates creative integration of available data/information, with future trial data, to accelerate drug development in an efficient, cost effective and ethical manner.
Pharmetheus
  • Has expertise in model informed drug development (MIDD) to support and inform study and program strategies and decisions.
  • Has a track record of efficient delivery of fit for purpose solutions, including complex situations.
  • Has access to a broad range of complementary drug research and development disciplines (including pharmacometrics, clinical pharmacology, statistics and regulatory) and academic subject matter experts.

Pharmetheus: transforming quality science to informed decisions

Drug development moves at a swift pace in an ever-changing competitive landscape and project teams are constantly facing new challenges, demanding a flexible proactive and adaptive mindset.
Pharmetheus
  • Offers a broad range of fit for purpose analytical solutions, including data programming, across all phases of research and development (incorporating submission and post approval activities).
  • Has a broad resource pool to accommodate varying needs, including modeling, training, interaction with regulatory bodies, expert advice and full-time equivalent support.
  • Has experience of, and expertise in, a wide range of therapeutic areas.

Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug development decisions.

Our Communications

Latest news from Pharmetheus

Rosenön award

We want to congratulate Christine Wegler, winner of the (co-sponsored by Pharmetheus), presented by the Swedish Pharmaceutical Society today. Read more here (in Swedish).

COVID-19 impact


Pharmetheus continues to monitor the challenges presented by the COVID-19 pandemic and its effects on our company and in the field of clinical drug development. Read more about our approach and latest updates here.

Pharmetheus featured in Pharma Tech Outlook magazine

Our CEO, Dr Peter A Milligan, has been interviewed by the Pharma Tech Outlook magazine. Read more about how we change the model informed drug development landscape of the pharmaceutical industry with our cutting-edge tools and methods, from early clinical trials to drug approval. Read the full interview here.

Top Pharma Analytics company

We are honoured that Pharmetheus has been listed as one of the top 10 pharma analytics companies in Europe by the Pharma Tech Outlook magazine for our Model Informed Drug Development consulting services. Read more here.

American Society of Hematology Annual Meeting & Exposition 2020

We are present at the American Society of Hematology Annual Meeting & Exposition 2020. On Saturday, December 5, Daniel Röshammar will present on age and body weight adjusted dosing of dabigatran etexilate in children with venous thromboembolism (Abstract 891). He is also co-author to the Abstract 236; Anticoagulant effects of dabigatran on coagulation laboratory parameters in paediatric patients: combined data from five paediatric clinical trials.

Additional PBPK publication

Our Pharmetheus colleague Erik Sjögren is co-author to one additional new publication on physiologically based biopharmaceutics models, including case studies. This workshop report summarizes the proceedings of Day 3 of a three-day workshop on “Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls. Link to publication

Introduction to our MIDD framework

We are advancing model informed drug development. In this video, Peter A Milligan describes our framework and some benefits of adopting these solutions across the project portfolio in terms of improved decision making, efficiency and return of investment.

Introduction to Pharmetheus

We have been in the business for 8 years now. In this video Elodie Plan and Marie Sandström explain who we are and where we are heading.

Welcome Fanny Gallais!

We are happy to have Fanny onboard as a MIDD consultant. Her research experience includes PK/PD modeling and simulations of preclinical and clinical data in oncology. Fanny will first work from her home office in France and then join our Uppsala office in Sweden in January. See her bio here.

Poster presentation

See the poster presentation of Population RTTE analysis of exacerbations in asthma patients by our MIDD Consultant Robin Svensson, presented at the American Conference on Pharmacometrics, November 2020

Welcome Andrea Henrich!

We are happy to have Andrea onboard as a MIDD consultant. Her research experience, from academia as well as pharmaceutical industry, includes PK/PD modeling and simulations in different therapeutic areas and concentration-QT analysis. Andrea will work from our Basel office in Switzerland. See her bio here

Free Virtual Speed Consulting

Pharmetheus will offer virtual professional pharmacometrics consulting sessions (~30 min), free of charge, between 5th and 20th of November in connection to the ACoP meeting.
Read more about the offer here.

New MIDD publication

Read more on the importance of collaboration for successful implementation Model Informed Drug Development. Richard Anziano, Chief Statistician and Peter A Milligan, CEO at Pharmetheus gives their perspective on this topic in the latest issue of Clinical Pharmacology & Therapeutics. Link to publication

New PBPK publication

Our Pharmetheus colleague Erik Sjögren is co-author to a new publication on physiologically based biopharmaceutics models. This workshop report summarizes the proceedings of Day 1 of a three-day workshop on “Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls”. Link to publication

We are hiring!

Pharmetheus is looking for a Quality Control – Medical Writer Consultant to support our team. Read more here here.

Welcome Quentin Leirens!

We are happy to have Quentin onboard in our Enabling team. Previously he was as a scientist at SGS Exprimo (2011-2020). His research experience includes model-based simulations for supporting drug development decision making, many of which have been submission projects. He has been extensively involved in the development of the Simulo software for clinical trial simulation. Quentin will work from his home office in Belgium. See his bio here.

Services

Our services include quantitative analyses by scientists with extensive therapeutic area experience industry, academic and regularly settings.

Our team

Pharmetheus consultants and advisors present a unique collection of experiences and combination of skill sets.
Senior Consultant, Quality Control Reviewer and Medical Writer
Senior Consultant, MIDD
Board Member
Principal Consultant, Chief Statistician, MIDD
Principal Consultant, MIDD. Board Member.
Senior Consultant, MIDD
Consultant, MIDD
Consultant, System Developer, MIDD
Consultant, Data Programmer
Board Member
Consultant, MIDD
Associate Consultant, Data Programmer
Principal Consultant, MIDD
Consultant, Data Programmer. Data Programming Manager.
Associate Consultant, MIDD
Associate Consultant, MIDD
Senior Consultant, MIDD
System Administrator
Consultant, MIDD
Consultant, MIDD
Associate Consultant, MIDD
Principal Consultant, MIDD
Senior Consultant, MIDD
Senior Consultant, MIDD
Project Coordinator
Board Chair, Advisor
Analyst Consultant, System Administrator
Consultant, MIDD
Consultant, MIDD
Associate Consultant, Systems Developer, MIDD
Administrative Assistant
Principal Consultant, MIDD
Consultant, MIDD
Chief Executive Officer
Analyst Consultant, Quality Control Reviewer and Medical Writer
Consultant, MIDD
Principal Consultant, Enabler Leader
Administrative Assistant
Senior Consultant, IT Manager
Principal Consultant, MIDD. Board Member.
Contract Manager
Consultant, Data Programmer
Consultant, MIDD

Request our services

If you are interested in our services, please fill out the form below.

How we work

Our way of working, with traceability and accountability from data programming to report delivery, is well adapted to, and highly compatible with, current regulatory requirements.